An analysis of inadequately controlled asthma patients with and without co-morbid allergic rhinitis treated with add-on montelukast

被引：0
|
作者：
Virchow, J. [1 ]
Mehta, A. [2 ]
Ljungblad, L. [3 ]
Mitfessel, H. [4 ]
机构：
[1] Univ Rostock, Dept Pneumol, Rostock, Germany
[2] Merck Res Labs, Clin & Quantitat Sci, Rahway, NJ USA
[3] Kendle GmbH, Biometr, Munich, Germany
[4] Pneumol Praxis, Allergol, Remscheid, Germany
来源：
ALLERGY | 2009年 / 64卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
431
引用
收藏
页码：183 / 183
页数：1
相关论文
共 50 条
  • [41] A subgroup analysis of the MONICA study: a 12-month, open-label study of add-on montelukast treatment in asthma patients (vol 47, pg 986, 2010)
    Virchow, J. Christian
    [J]. JOURNAL OF ASTHMA, 2011, 48 (06) : 650 - 652
  • [42] COST-MINIMIZATION ANALYSIS OF SQ® HDM SLIT-TABLET IN PATIENTS WITH HOUSE DUST MITE ALLERGIC RHINITIS WITH OR WITHOUT ALLERGIC ASTHMA IN POLAND
    Obrzut, G.
    Augustynska, J.
    Walczak, J.
    Buchs, S.
    [J]. VALUE IN HEALTH, 2018, 21 : S413 - S413
  • [43] COST-UTILITY ANALYSIS OF SQ® HDM SLIT-TABLET IN PATIENTS WITH HOUSE DUST MITE ALLERGIC RHINITIS WITH OR WITHOUT ALLERGIC ASTHMA IN POLAND
    Obrzut, G.
    Augustynska, J.
    Walczak, J.
    Buchs, S.
    [J]. VALUE IN HEALTH, 2018, 21 : S413 - S413
  • [44] Evaluation of 3-5 months' add-on therapy with montelukast in patients with non-controlled asthma in Austria: the STAR open-label, real-world, observational study
    Schlick, Werner
    Pohl, Wolfgang
    Pfeiffer, Karl P.
    Aigner, Kurt
    Forche, Guenter
    Kneussl, Meinhard
    Zwick, Hartmut
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2010, 26 (03) : 561 - 570
  • [45] Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic (immunoglobulin E-mediated) asthma: A subgroup analysis of an open label trial
    Chung, K.
    Niven, R.
    Panahloo, Z.
    Blogg, M.
    Ayre, G.
    [J]. ALLERGY, 2007, 62 : 144 - 145
  • [46] Rates of asthma attacks in patients with previously inadequately controlled mild asthma treated in clinical practice with combination drug therapy: An exploratory post-hoc analysis
    Dal Negro R.W.
    Borderias L.
    Zhang Q.
    Fan T.
    Sazonov V.
    Guilera M.
    Taylor S.D.
    [J]. BMC Pulmonary Medicine, 9 (1)
  • [47] Comparison of adverse events between cluster and conventional immunotherapy for allergic rhinitis patients with or without asthma: A systematic review and meta-analysis
    Jiang, Zihan
    Xiao, Hao
    Zhang, Hongting
    Liu, Shixi
    Meng, Juan
    [J]. AMERICAN JOURNAL OF OTOLARYNGOLOGY, 2019, 40 (06)
  • [48] The beneficial effects of Xolair® (omalizumab) as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available treatment (GINA 2002 step IV) -: The Israeli arm of the INNOVATE study
    Sthoeger, Zev M.
    Eliraz, Abraham
    Asher, Ilan
    Berkman, Neville
    Elbirt, Daniel
    [J]. ISRAEL MEDICAL ASSOCIATION JOURNAL, 2007, 9 (06): : 472 - 475
  • [49] Once-daily tiotropium Respimat® as add-on to at least medium- to high-dose ICS, with or without LABA, improves lung function in patients with symptomatic asthma, independent of allergic status
    Dahl, R.
    Bateman, E. D.
    Casale, T.
    Pizzichini, E.
    Vandewalker, M.
    Virchow, J. C.
    Engel, M.
    Sigmund, R.
    Moroni-Zentgraf, P.
    Kerstjens, H. A. M.
    [J]. ALLERGY, 2014, 69 : 515 - 515
  • [50] Liraglutide as add-on to sodium-glucose co-transporter-2 inhibitors in patients with inadequately controlled type 2 diabetes: LIRA-ADD2SGLT2i, a 26-week, randomized, double-blind, placebo-controlled trial
    Blonde, Lawrence
    Belousova, Lidia
    Fainberg, Udi
    Garcia-Hernandez, Pedro A.
    Jain, Sunil M.
    Kaltoft, Margit S.
    Mosenzon, Ofri
    Nafach, Jalal
    Palle, Mads Sundby
    Rea, Rosangela
    [J]. DIABETES OBESITY & METABOLISM, 2020, 22 (06): : 929 - 937
12345